New Releases from NCBI BookshelfNivolumab: Therapeutic Area: Hodgkin lymphoma: Reimbursement Review [Internet].​Nivolumab: Therapeutic Area: Hodgkin lymphoma: Reimbursement Review [Internet].

Classic Hodgkin lymphoma (cHL) is a relatively rare cancer of the immune system that contains abnormal B lymphocytes called Reed-Sternberg cells in the lymph nodes. cHL is the most common type of Hodgkin lymphoma, accounting for 95% of all Hodgkin lymphoma cases. The other 5% of Hodgkin lymphoma cases are nodular lymphocyte-predominant Hodgkin lymphoma.

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top